Carbon Reduction Plan

Supplier name: Gore UK Medical Limited

Publication date: 6/11/2025

Commitment to achieving Net Zero

Gore UK Medical Limited ("Gore UK Medical") is committed to achieving Net Zero emissions by 2050.

About Gore

Gore UK Medical is a wholly owned subsidiary of W. L. Gore & Associates, Inc. (also referred to as "Enterprise" or "Gore" throughout this document).

Gore is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world's highest peaks to the inner workings of the human body. With approximately 12,600 Associates and a strong, team-oriented culture, Gore generates annual revenues of \$5.3 billion.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases (GHGs) that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2016 (Calendar Year)

Additional Details relating to the Baseline Emissions calculations.

The Enterprise has adopted a science-based approach to adequately address its fair share of GHG emissions reduction and calculates these emissions using the GHG Protocol Corporate Standard.

Gore UK Medical does not own or operate any manufacturing facilities within the United Kingdom. Its parent company, W. L. Gore & Associates, Inc., manufactures medical devices outside the UK and supplies them to Gore UK Medical.

Gore measures greenhouse gas (GHC) emissions at the Enterprise level and allocates these emissions across four business groups: Gore Medical, Gore Fabrics, Gore Performance Solutions, and Gore Specialty.

The portion of emissions attributed to Gore Medical has been further allocated to Gore UK Medical using a revenue-based allocation method.

Scope 3 emissions have not yet been published but the Enterprise plans to establish its baseline in FY2026.			
Baseline year emissions: 2016 (Scope 1 & 2)			
EMISSIONS	TOTAL (tCO ₂ e)		
Scope 1	86 (emissions due to company cars) 344 (allocated emissions from parent company)		
Scope 2	0 (emissions due to company cars) 636 (allocated emissions from parent company)		
Scope 3 (Included Sources)	In 2023, Gore launched an Enterprise-wide effort to begin calculating Scope 3 GHG emissions. Throughout 2024 and the beginning of 2025, teams across the Enterprise collaborated to establish standardized Scope 3 accounting practices in preparation for external reporting. Gore plans to begin disclosing Scope 3 data in 2026 for the Fiscal Year 2026 period, focusing on delivering relevant, actionable insights.		
Total Emissions	1066		

Current Emissions Reporting

Reporting Year: 2025 (Fiscal Year)		
EMISSIONS	Gore UK TOTAL (tCO ₂ e)	
Scope 1	33 (emissions due to company cars) 363 (allocated emissions from parent company)	
Scope 2	6 (emissions due to company cars) 94 (allocated emissions from parent company)	
Scope 3 (Included Sources)	N/A. See above.	
Total Emissions	496	

Emissions reduction targets


W. L. Gore & Associates, Inc. has adopted the following Enterprise-wide carbon reduction targets.

- Achieve 50% reduction in the Enterprise's absolute scope 1 & 2 carbon emissions by the end of 2025 as a milestone toward meeting the 2030 goal.
- Achieve 60% reduction in the Enterprise's absolute scope 1 & 2 carbon emissions by 2030.
- Work to increase use of renewable electricity in manufacturing facilities to 100% by the end of 2025.

The Enterprise's latest progress toward achieving these global goals and other Sustainability efforts can be found in the recent Enterprise Sustainability Update:

https://www.gore.com/resources/enterprise-sustainability-update-2024

Gore is progressing against these Enterprise targets as shown in the graph below. NOTE: Quantities are shown in **kt** CO₂e as is consistent with our Enterprise Sustainability Update:



Carbon Reduction Projects

Carbon Reduction Initiatives

Currently, the Enterprise strategy prioritizes emissions reductions, and does not participate in carbon offset programs. These carbon reduction initiatives and projects are listed in Gore's Enterprise Sustainability Update referenced in the above section.

Gore UK Medical aims to reduce emissions by continued deployment of the following carbon reduction activities in the UK:

Scope 1 & 2	Car Fleet	Engagement with Associates to encourage more efficient, low-emission vehicle fleet, including hybrid and electric cars, among our sales and support teams.
Scope 3	Transportation & Distribution	Project with Gore UK Medical's transportation and distribution service providers in Europe to find collaborative ways to reduce scope 3 emissions.
	Single Use Recycling	Conceptualize and pilot a carbon reduction initiative focused on recycling selected single-use medical devices. The project aims to reduce Scope 3 emissions by identifying high-impact devices, assessing recycling feasibility, and partnering with certified processors. The pilot phase will be implemented in one to two NHS hospitals.

Declaration and Sign-off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard1 and uses the appropriate Government emission conversion factors for GHG company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and internal goals for the completion of baseline and current emissions for the relevant subset of Scope 3 emissions have been provided per the explanations in "Baseline Emissions Footprint" and "Current Emissions Reporting" sections above.

This Carbon Reduction Plan has been reviewed and approved by members of the Board of Directors of Gore UK Medical Limited on November 6th, 2025.

Signed on behalf of the Supplier:

Michael Hullik

Director, Gore UK Medical Limited

6 November 2025

https://ghgprotocol.org/corporate-standard

²https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting

Gore UK Medical Limited Carbon Reduction Plan



Together, improving life

GORE UK MEDICAL LTD

Simpson Parkway, Kirkton Campus, Livingston West Lothian EH54 7BH, SCOTLAND T +44 (0) 1506 460123 F +44 (0) 1506 420004 gore.co.uk/medical-ltd

GORE, Together, Improving life and designs are trademarks of W. L. Gore & Associates

Registered Office: 27 Old Gloucester Street, London, WC1N 3AX, ENGLAND

VAT ID: GB261591696